<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">The prevalence of co-infection varied among COVID-19 patients, ranging from 0% to 50% among non-survivors. Reported co-pathogens included bacteria, such as 
 <italic>Mycoplasma pneumoniae</italic>, 
 <italic>Candida</italic> species, and viruses (influenza, rhinovirus, coronavirus, and HIV). Influenza A virus was the commonest co-infective virus.
 <xref rid="bib59" ref-type="bibr">
  <sup>59</sup>
 </xref> Co-administration of anti-influenza agents and anti-bacterial agents in patients with COVID-19 pneumonia was common.
 <xref rid="bib59" ref-type="bibr">
  <sup>59</sup>
 </xref> Consequently, a cautious prescription of effective antibiotic(s) covering 
 <italic>Staphylococcus aureus</italic> (including methicillin-resistant 
 <italic>S. aureus</italic>), multidrug-resistant 
 <italic>Streptococcus pneumoniae</italic>, 
 <italic>Klebsiella pneumoniae</italic>, and 
 <italic>Pseudomonas aeruginosa</italic> as well as 
 <italic>Acinetobacter baumannii</italic> species for patients undergoing long hospitalization (&gt;6 days) is advised.
 <xref rid="bib60" ref-type="bibr">
  <sup>60</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib61" ref-type="bibr">
  <sup>61</sup>
 </xref>
</p>
